. Author manuscript; available in PMC: 2014 Jul 3.

Published in final edited form as: Bone Marrow Transplant. 2009 Aug 10;45(3):429–436. doi: 10.1038/bmt.2009.189

Table 1.

Characteristics of 28 patients with hematological malignancies treated with FMT preparative regimen

	FMT (n = 28)
Median age (years) (range)	36 (6–54)
Gender (%)
M	46
F	54
Donor (%)
Child	21
Parent	32
Sibling	47
Cell type (%)
PB	100
BM	0
Disease (number of patients)
AML/MDS	22
ALL	3
CML blast phase	2
Peripheral T-cell lymphoma	1
Cytogenetic risk (%) (for patients with acute leukemia/MDS) (n = 25)
Poor	48
Intermediate	52
Median % of BM blasts at transplant (for patients AML/MDS; n = 22) (range)	13 (0–92)
Median number of Ag mismatches	3
Median number of CD34 cells infused ( × 10⁶) (range)	10.2 (6–20.85)
Median number of CD3 cells infused (× 10⁶)	0.01

Abbreviations: F = female; FMT = fludrabine, melphalan and thiotepa and antithymocyte globulin; M = male; MDS = myelodyspastic syndrome; PB = peripheral blood.